| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 01/14/2003 | US6506587 Nucleotide sequences coding enzymatic polypeptide; for use as an antitumor a gents |
| 01/14/2003 | US6506555 Use of HIV protease inhibiting compounds |
| 01/14/2003 | US6506414 Homogenizing a tissue in a nondenaturing aqueous solvent to obtain particles; aqueous solvent extraction; separation of solid and liquid; fractionating and purifying; inhibitors of matrix metalloprotease and angiogenesis; antitumor agents |
| 01/14/2003 | US6506381 Modified red blood cell that has surface molecules that neutralize chemical agents |
| 01/14/2003 | CA2217477C Tricyclic compounds useful for inhibition of farnesyl protein transferase |
| 01/14/2003 | CA2194444C Immunomodulators |
| 01/14/2003 | CA2116859C Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone |
| 01/14/2003 | CA2114313C Bpc peptides, their preparation and use |
| 01/14/2003 | CA2023089C Method for the treatment of cardiac and of vascular hypertrophy and hyperplasia |
| 01/13/2003 | CA2393376A1 Assay methods |
| 01/09/2003 | WO2003003018A2 Method for identifying compounds for the therapy of aging of the cardiovascular system |
| 01/09/2003 | WO2003003011A1 Modification of angiogenesis by targeting protein tyrosine phosphatases |
| 01/09/2003 | WO2003003004A2 Method for identifying compounds the specifically deplete mast cells |
| 01/09/2003 | WO2003002742A1 Nucleic acid participating in the formation of presenilin-2-gene exon 5-defective splicing variant |
| 01/09/2003 | WO2003002722A2 T cell regulatory genes and methods of use thereof |
| 01/09/2003 | WO2003002610A1 Extracellular messengers |
| 01/09/2003 | WO2003002598A2 Peptides for use as translocation factors |
| 01/09/2003 | WO2003002596A2 Use of dipeptidyl peptidase iv inhibitors as therapeutics for neurological disorders |
| 01/09/2003 | WO2003002595A2 Dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents |
| 01/09/2003 | WO2003002593A2 Peptide structures useful for competitive modulation of dipeptidyl peptidase iv catalysis |
| 01/09/2003 | WO2003002584A1 NOVEL GALACTOSYLCERAMIDE ANALOGS AND β-GLUCOCEREBROSIDASE ACTIVATORS, EXTERNAL SKIN PREPARATIONS AND METHOD OF ACTIVATING β-GLUCOCEREBROSIDASE USING THE ANALOGS |
| 01/09/2003 | WO2003002575A1 3-ARYL-$G(a)-OXY SUBSTITUTED PROPANOIC ACIDS AND A PROCESS FOR THEIR PREPARATION |
| 01/09/2003 | WO2003002568A1 Carbohydrate derivatives |
| 01/09/2003 | WO2003002566A1 Purine derivatives as a2b adenosine receptor antagonists |
| 01/09/2003 | WO2003002565A1 2,6,9-substituted purine derivatives and their use n the treatment of proliferative disorders |
| 01/09/2003 | WO2003002559A2 Piperidine compounds for use as orexin receptor antagonist |
| 01/09/2003 | WO2003002558A1 Remedial agent for viral infectious disease |
| 01/09/2003 | WO2003002556A1 Novel heteroaryl derivatives, their preparation and use |
| 01/09/2003 | WO2003002554A1 Piperazine compounds |
| 01/09/2003 | WO2003002552A1 Novel indole derivatives |
| 01/09/2003 | WO2003002549A1 Eurotinone and derivatives thereof, method for the production and use of the same |
| 01/09/2003 | WO2003002544A1 N-heterocyclic inhibitors of tnf-alpha expression |
| 01/09/2003 | WO2003002540A1 Cyclic diamine compound having five-membered cyclic group |
| 01/09/2003 | WO2003002539A1 Dibenzocycloheptene compound |
| 01/09/2003 | WO2003002538A1 Bis(2-aryl-5-pyridyl) derivative |
| 01/09/2003 | WO2003002537A1 Bis(5-aryl-2-pyridyl) derivative |
| 01/09/2003 | WO2003002535A1 Cyclic diamine compounds bearing six-membered cyclic groups |
| 01/09/2003 | WO2003002533A1 Triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (mtp) and/or apolipoprotein b (apo b) secretion |
| 01/09/2003 | WO2003002532A1 Cyclic diamine compounds having fused-ring groups |
| 01/09/2003 | WO2003002531A2 Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| 01/09/2003 | WO2003002530A2 Pyrrolidines as dipeptidyl peptidase inhibitors |
| 01/09/2003 | WO2003002511A1 Cycloalkenone derivative |
| 01/09/2003 | WO2003002173A1 Process and apparatus for utilization of in vivo extracted plasma with tissue engineering devices, bioreactors, artificial organs, and cell therapy applications |
| 01/09/2003 | WO2003002152A2 Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins |
| 01/09/2003 | WO2003002147A1 Preventives/remedies for organ functional disorders and organ dysfunction |
| 01/09/2003 | WO2003002146A1 Medicinal compositions |
| 01/09/2003 | WO2003002145A1 Diagnosis and treatment of insulin-dependent diabetes mellitus and insulitis |
| 01/09/2003 | WO2003002140A1 Use of poly-glu, tyr and t cells treated therewith for neuroprotection therapy |
| 01/09/2003 | WO2003002129A1 Use of sulodexide for the treatment of inflammatory bowel disease |
| 01/09/2003 | WO2003002127A1 Use of at least one glycoinhibitor substance |
| 01/09/2003 | WO2003002123A2 Therapeutic combinations for the treatment of hormone deficiencies |
| 01/09/2003 | WO2003002118A1 Substituted 8-arylquinoline pde4 inhibitors |
| 01/09/2003 | WO2003002114A2 Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis |
| 01/09/2003 | WO2003002110A1 METHODS FOR PREPARATION AND USE OF 1α,24(S)-DIHYDROXYVITAMIN D¿2? |
| 01/09/2003 | WO2003002109A2 Use of tyrosine kinase inhibitors for treating autoimmune diseases |
| 01/09/2003 | WO2003002108A2 Use of tyrosine kinase inhibitors for treating inflammatory diseases |
| 01/09/2003 | WO2003002106A2 Use of tyrosine kinase inhibitions for treating allergic diseases |
| 01/09/2003 | WO2003002105A2 Use of tyrosine kinase inhibitors for treating bone loss |
| 01/09/2003 | WO2003002092A2 Controlled release composition comprising lactic acid polymer and hydroxynaphthoic acid, and method of producing the same |
| 01/09/2003 | WO2003002088A2 Use of an oil of the gourd family for inhibiting 5$g(a)-reductase activity |
| 01/09/2003 | WO2003001881A2 Cell-based high-throughput screening methods |
| 01/09/2003 | WO2002092825A3 Retroviral vectors for gene therapy |
| 01/09/2003 | WO2002087612A3 Use of stimulated peripheral blood mononuclear cells for treating cancerous diseases |
| 01/09/2003 | WO2002087591A3 Use of derivatives of spironolactone like canrenone as anti-fibrogegic drug |
| 01/09/2003 | WO2002083674A3 Compositions containing imidazotriazinone for nasal application |
| 01/09/2003 | WO2002076376A3 A stable pharmaceutical composition of pravastatin |
| 01/09/2003 | WO2002071874A3 Composition improving age-related physiological deficits and increasing longevity |
| 01/09/2003 | WO2002069994A3 Combined use of derivatives of glp-1 analogs and ppar ligands |
| 01/09/2003 | WO2002062777A9 Amino ceramide-like compounds and therapeutic methods of use |
| 01/09/2003 | WO2002059111A3 Pyrazole compounds useful as protein kinase inhibitors |
| 01/09/2003 | WO2002057231A3 Benz(g) indoles and their use as spla2 inhibitors |
| 01/09/2003 | WO2002049622A3 Transdermal system containing a novel high potency progestagen |
| 01/09/2003 | WO2002046423A3 Protein derived from the melanin-concentrating hormone (mch), corresponding nucleic acids and their use for preparing medicines |
| 01/09/2003 | WO2002046373A9 Method of collecting placental stem cells |
| 01/09/2003 | WO2002044320A3 Human elongase genes and uses thereof |
| 01/09/2003 | WO2002043664A3 Reducing cellular damage in the human body |
| 01/09/2003 | WO2002042437A3 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| 01/09/2003 | WO2002036097A3 Delivery system for entrapping charged macromolecules and a method for preparing same |
| 01/09/2003 | WO2002032953A3 Pregnancy-associated plasma protein-a2 (papp-a2) |
| 01/09/2003 | WO2002024726A3 Olfactory and pheromones g-protein coupled receptors |
| 01/09/2003 | WO2002009716A3 Use of an aldehyde 5-oxo-1,2,4-triazine hydrazide for the treatment of cancer |
| 01/09/2003 | WO2002008251A3 Peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 01/09/2003 | WO2002003970A2 Matrix controlled transdermal system for stabile derivatives of ace inhibitors |
| 01/09/2003 | WO2001098351A3 G-protein coupled receptors |
| 01/09/2003 | WO2001097793A3 2-arachidonylglycerol (2-ag) - an inhibitor of tumor necrosis factor -alfa and neuroprotector of brain in closed head injury |
| 01/09/2003 | WO2001079480A9 Albumin fusion proteins |
| 01/09/2003 | WO2001072728B1 Novel piperazine derivatives |
| 01/09/2003 | WO2001070213A3 Bactericidal antimicrobial methods and compositions for use in treating gram positive infections comprising an antibiotic potentiator having acyl hydrazide oxy amide or 8-hydroxy quinoline structure |
| 01/09/2003 | WO2001068637A3 Method for the preparation of tetrahydrobenzothiepines |
| 01/09/2003 | WO2001057267A9 Methods and materials relating to cub domain polypeptides and polynucleotides |
| 01/09/2003 | WO2001056532A9 Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc) |
| 01/09/2003 | WO2001055336A9 Methods and materials relating to cd84-like polypeptides and polynucleotides |
| 01/09/2003 | US20030009777 Using galanin agonist in the generation of medicament for the treatment of nerve damage |
| 01/09/2003 | US20030009036 To produce polymers; cancer therapy |
| 01/09/2003 | US20030009032 For inhibiting the replication or infectivity of a virus; therapy |
| 01/09/2003 | US20030008924 Providing cell which overexpresses a Bcl-2 family protein; gossypol compound; treating with cell with an effective amount of gossypol compound under conditions such that apoptosis in cell is modulated |
| 01/09/2003 | US20030008915 Acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amines and their use as pharmaceutical agents |
| 01/09/2003 | US20030008911 Treating or preventing the early stages of degeneration of articular cartilage or subchondral bone in mammals using carprofen and derivatives |
| 01/09/2003 | US20030008910 Use of proteasome inhibitors to treat dry eye disorders |
| 01/09/2003 | US20030008909 For therapy of uterine myometrial fibroids, endometriosis, benign prostatic hypertrophy; carcinomas and adenocarcinomas of endometrium, ovary, breast, colon, prostate, pituitary, meningioma and other hormone-dependent tumors |